A comparative study of the effects of gestodene 60 µg/ethinylestradiol 15 µg and desogestrel 150 µg/ethinylestradiol 20 µg on hemostatic balance, blood lipid levels and carbohydrate metabolism

REFERENCES

• Speroff L, DeCherney A. Evaluation of a new generation of oral contraceptives. Obstet Gyuecol 1993; 81: 1034–47
   PubMed Web of Science ®Google Scholar
• Daly L, Bonnar J. Comparative studies of 30 micrograms ethinylestradiol combined with gestodene and desogestrel on blood coagulation, fibrinolysis, and platelets. Am J Obstet Gynecol 1990; 163: 430–7
   PubMed Web of Science ®Google Scholar
• Fotherby K, Caldwell A. New progestogens in oral contraception. Contraception 1994; 49: 1–32
   PubMed Web of Science ®Google Scholar
• Wynn V, Doar J. Some effects of oral contraceptives on carbohydrate metabolism. Lancet 1966; 2: 715–19
   PubMed Web of Science ®Google Scholar
• Spellacy W, Buhi W, Birk S. Effect of estrogen treatment for one year on carbohydrate and lipid metabolism in women with normal and abnormal glucose tolerance test results. Am J Obstet Gynecol 1978; 131: 87–90
   PubMed Web of Science ®Google Scholar
• Rebar R, Zeserson K. Characteristics of the new progestogens in combination oral contraceptive. Contraception 1991; 44: 1–10
   PubMed Web of Science ®Google Scholar
• Godsland I, Crook D, Simpson R, et al. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism. N Engl J Med 1990; 323: 1375–81
   PubMed Web of Science ®Google Scholar
• Kaplan B. Desogestrel, norgestimate, and gestodene: the newer progestins. Ann Pharmacother 1995; 29: 736–42
   PubMed Web of Science ®Google Scholar
• Kluft C, Lansink M. Effect of oral contraceptives on haemostasis variables. Thromb Haemost 1997; 78: 315–26
   PubMed Web of Science ®Google Scholar
• Shoupe D. New progestins - clinical experiences: gestodene. Am J Obstet Gynecol 1994; 170: 1562–8
   PubMed Web of Science ®Google Scholar
• Fotherby K. Desogestrel and gestodene in oral contraception: a review of European experience. J Drug Deu \99\; 4: 101–11
   Google Scholar
• Sullivan H, Furniss H, Spona J, Elstein M. Effect of 21-day and 24-day oral contraceptive regimens containing gestodene (60 |ig) and ethinyl estradiol (15 Hg) on ovarian activity. Fértil Steril 1999; 72: 115–20
   PubMed Web of Science ®Google Scholar
• Koppert PW, Hoegee-de Nobel E, Nieuwenhuizen W. A monoclonal antibody-based enzyme immunoassay for fibrin degradation products in plasma. Thromb Haemost 1988; 59: 310–15
   PubMed Web of Science ®Google Scholar
• Clauss A von. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237–46
   PubMedGoogle Scholar
• Avvisati G. Evaluation of a new chromogenic assay for factor VII and its application in patients on oral anticoagulant treatment. Br J Haematol 1980; 45: 343–52
   PubMed Web of Science ®Google Scholar
• Morrissey JH, Macik BG, Neuenschwander PF, et al. Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 1993; 81: 734—44
   PubMed Web of Science ®Google Scholar
• Pelzer H, Schwarz A, Stuber W. Determination of human prothrombin fragment in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991; 65: 153–9
   PubMed Web of Science ®Google Scholar
• Gram J, Jespersen J. A functional plasminogen assay utilising the potentiating effect of fibrinogen to correct for the overestimation of plasminogen in pathological plasma samples. Thromb Haemost 1985; 53: 255–9
   PubMed Web of Science ®Google Scholar
• Pelzer H, Pilgrim A, Schwarz A, et al. Determination of alpha-2-antiplasmin complex in human plasma with an enzyme-linked immunosorbent assay. Fibrinolysis 1993; 7: 69–74
   Google Scholar
• Ranby M, Nguyen C, Scarabin PY, et al. Immunoreactivity of tissue plasminogen activator and of its inhibitor complexes. Biochemical and multicenter validation of a two site immunosorbent assay. Tliromb Haemost 1989; 61: 409–14
   PubMed Web of Science ®Google Scholar
• Meijer P, Pollet DE, Wauters J, et al. Specificity of antigen assays of plasminogen activator inhibitor in plasma: innotest PAI-1 immunoassay evaluated. Clin Chan 1994; 40: 110–15
   PubMed Web of Science ®Google Scholar
• Kluft C. Disorders of the hemostatic system and the risk of the development of thrombotic and cardiovascular diseases: limitations of laboratory diagnosis. Am J Obstet Gynecol 1990; 163: 305–12
   PubMed Web of Science ®Google Scholar
• Winkler UH, Koslowski S, Oberhoff C, et al. Changes of the dynamic equilibrium of hemostasis associated with the use of low-dose oral contraceptives. Adv Contracept 1991;7(Suppl3): 273–84
   Google Scholar
• Kluft C, Verheijen JH. Leiden fibrinolysis working party: blood collection and handling procedures for assessment of tissue-type plasminogen activator (t-PA) and plasminogen activator inhibitor (PAI 1). Fibrinolysis 1990; 4: 155–61
   Google Scholar
• Kluft C, Meijer P. Update 1996: blood collection and handling procedures for assessment of plasminogen activators and and inhibitors (Leiden Fibrinolysis Workshop). Fibrinolysis 1996; 10 (Suppl): 2171–9
   Google Scholar
• Petersen KR, Sidelmann J, Skouby SO, et al. Effects of monophasic low-dose oral contraceptives on fibrin formation and resolution in young women. Am J Obstet Gynecol 1993; 168 (part 1): 32–8
   Google Scholar
• Baird D, Glasier A. Hormonal contraception. N Engl J Med 1993; 328: 1543–9
   PubMed Web of Science ®Google Scholar
• Brown G, Albers JJ, Fisher LD, et al. Regression of coronary artery disease as a result of intensive lipidio wering therapy in men with high levels of apolipoprotein B. NEngl J Med 1990; 323: 1289–95
   PubMed Web of Science ®Google Scholar
• Walsh J, Grady D. Treatment of hyperlipidemia in women. J Am Med Assoc 1995; 274: 1152–8
   PubMed Web of Science ®Google Scholar
• Marsh MS, Crook D, Whitcroft SIJ, et al. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins. Obstet Gynecol 1994; 83: 19–23
   PubMed Web of Science ®Google Scholar
• Spellacy W, Tsibris A, Tsibris J, et al. Carbohydrate metabolism studies after one year of using an oral contraceptive containing gestodene and ethinylestradiol. Contraception 1994; 49: 125–30
   PubMed Web of Science ®Google Scholar